210 related articles for article (PubMed ID: 38794172)
1. Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview.
Seane EN; Nair S; Vandevoorde C; Joubert A
Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794172
[TBL] [Abstract][Full Text] [Related]
2. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
3. Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells.
Di Bernardo G; Alessio N; Dell'Aversana C; Casale F; Teti D; Cipollaro M; Altucci L; Galderisi U
J Cell Physiol; 2010 Nov; 225(2):537-44. PubMed ID: 20458754
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors and rational combination therapies.
Grant S; Dai Y
Adv Cancer Res; 2012; 116():199-237. PubMed ID: 23088872
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
Jonsson M; Ragnum HB; Julin CH; Yeramian A; Clancy T; Frikstad KM; Seierstad T; Stokke T; Matias-Guiu X; Ree AH; Flatmark K; Lyng H
Br J Cancer; 2016 Oct; 115(8):929-939. PubMed ID: 27599042
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
Feng W; Zhang B; Cai D; Zou X
Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
[TBL] [Abstract][Full Text] [Related]
8. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.
Zhou M; Yuan M; Zhang M; Lei C; Aras O; Zhang X; An F
Eur J Med Chem; 2021 Dec; 226():113825. PubMed ID: 34562854
[TBL] [Abstract][Full Text] [Related]
9. HDAC inhibitors: roles of DNA damage and repair.
Robert C; Rassool FV
Adv Cancer Res; 2012; 116():87-129. PubMed ID: 23088869
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.
Groselj B; Sharma NL; Hamdy FC; Kerr M; Kiltie AE
Br J Cancer; 2013 Mar; 108(4):748-54. PubMed ID: 23361058
[TBL] [Abstract][Full Text] [Related]
11. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives.
Pu J; Liu T; Wang X; Sharma A; Schmidt-Wolf IGH; Jiang L; Hou J
Exp Hematol Oncol; 2024 Apr; 13(1):45. PubMed ID: 38654286
[TBL] [Abstract][Full Text] [Related]
12. Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Yang H; Sun B; Xu K; He Y; Zhang T; Hall SRR; Tan ST; Schmid RA; Peng RW; Hu G; Yao F
EBioMedicine; 2021 Jul; 69():103457. PubMed ID: 34224975
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Slingerland M; Guchelaar HJ; Gelderblom H
Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
Koutsounas I; Giaginis C; Theocharis S
World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
[TBL] [Abstract][Full Text] [Related]
15. Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies.
Pal D; Raj K; Nandi SS; Sinha S; Mishra A; Mondal A; Lagoa R; Burcher JT; Bishayee A
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345145
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi).
Friedrich A; Assmann AS; Schumacher L; Stuijvenberg JV; Kassack MU; Schulz WA; Roos WP; Hansen FK; Pflieger M; Kurz T; Fritz G
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635356
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
19. Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.
Valiuliene G; Stirblyte I; Cicenaite D; Kaupinis A; Valius M; Navakauskiene R
J Cell Mol Med; 2015 Jul; 19(7):1742-55. PubMed ID: 25864732
[TBL] [Abstract][Full Text] [Related]
20. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
Lu G; Jin S; Lin S; Gong Y; Zhang L; Yang J; Mou W; Du J
Clin Epigenetics; 2023 Aug; 15(1):124. PubMed ID: 37533111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
